Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever

Johnson & Johnson’s newly launched psoriasis pill Icotyde is off to a solid start, with about 1,500 prescriptions written in less than 30 days after FDA approval in mid-March. The company is targeting Icotyde and Tremfya to replace declining Stelara sales, which peaked near $11 billion in 2023 and are expected to fall to $2.36 billion this year, while analysts differ on whether the pill can scale to blockbuster status. Leerink’s David Risinger raised his J&J price target to $265 and now sees Icotyde sales reaching $10.5 billion in 2032, but payer access and competition from biologic injections remain key risks.

Analysis

JNJ’s key inflection is not whether Icotyde becomes a meaningful psoriasis asset, but whether it changes the payer and physician framing of systemic therapy. The pill has a better chance of displacing low-conviction topical cycling than entrenched biologic users; that makes the near-term upside more about treatment-naive flow than broad share capture. The first real tell will be refill persistence and payer breadth by late summer, because launch scripts alone can overstate durable demand.

The competitive read-through is more nuanced for ABBV than for JNJ. If the class remains biologic-dominant, Skyrizi and Tremfya retain the “best-in-class” gravity and the oral entrant mostly expands the market at the margin; if payers force step-through economics, JNJ can harvest patients who would otherwise never reach injectables, while AMGN’s Otezla is the most exposed legacy oral. The biggest second-order issue is pricing pressure: a successful oral with lower manufacturing complexity could become the reference point in negotiations, eventually capping premium pricing across the IL-23/immune bucket.

The risk case is a familiar one: psoriasis pills often win headlines, then lose on adherence, efficacy, and durability versus injections. A 30-90 day script burst can fade quickly if patients dislike daily dosing or if access is patchy; that makes the first half of the summer the key catalyst window. Longer term, the bigger upside is inflammatory bowel disease, where even modest penetration can materially re-rate the asset, but that thesis is at least 2-3 years from validation and depends on clean label expansion.

Consensus is likely underestimating the portfolio effect on JNJ more than the standalone pill. If Icotyde becomes the preferred on-ramp to advanced immunology, it can defend share at the low end of the funnel while Tremfya/other assets capture escalations later, creating a multi-step monetization path rather than a single-product bet. The market may be over-focusing on whether a pill beats a shot head-to-head, when the real value is whether JNJ can own the sequencing of care.

Key Decisions for Investors

• Long JNJ on a 3-6 month horizon; add on any post-launch digestion if payer breadth improves by summer. Risk/reward favors holding for label-expansion optionality, with downside limited by diversified earnings.
• Pair long JNJ / short AMGN over 3-9 months. Icotyde is the cleaner threat to legacy oral immunology share, while JNJ’s biologic franchise can absorb any cannibalization better than AMGN’s smaller adjacent exposure.
• Buy ABBV on weakness rather than chase strength. If Icotyde mostly expands the market, ABBV’s Skyrizi should remain insulated; if the market is wrong and oral adoption accelerates, ABBV still owns the higher-efficacy biologic tier.
• Avoid shorting ISRG on this headline alone; there is no direct surgery-share read-through. Any move there should wait for evidence of broader healthcare spending rotation, not psoriasis launch data.
• Use a call spread in JNJ for 6-12 months rather than outright equity if you want to express Icotyde upside with defined risk; the event path is asymmetric, but near-term adoption volatility is high.